Animal and Human Imaging Shared Resource

动物和人类成像共享资源

基本信息

项目摘要

CORE 002 – ANIMAL AND HUMAN IMAGING SHARED RESOURCE PROJECT SUMMARY/ABSTRACT The Animal and Human Imaging Shared Resource (AHISR) has been continuously supported by the Cancer Center Support Grant (CCSG) since 2004. The AHISR provides scientific and technical assistance for experiments employing biomedical imaging for the study of cancer in both the pre-clinical and clinical settings and continues to undertake developments to meet ongoing needs. As in previous cycles, the AHISR remains a critical component of VICC’s Specialized Programs of Research Excellence (SPORE) programs, with both recently renewed Breast and Gastrointestinal (GI) SPOREs having featured imaging components. In 2018, the AHISR was integral to landing a new NCI-funded co-clinical imaging trial resource (U24) focused on quantitative PET imaging of cancer metabolism with investigational radiopharmaceuticals. Furthermore, the AHISR expertise and capabilities have enabled a new partnership between VICC and GE Health Care (GEHC), where quantitative cancer imaging and radiopharmaceutical discovery are central pillar programs of a major precision oncology initiative. The faculty and staff within the AHISR provide access to state-of-the-art imaging facilities including advanced human MRI systems operating at 3T and 7T, a research-dedicated PET/CT, ultrasound scanner, and a comprehensive facility for multimodal animal imaging and research radiopharmaceuticals for animal and human use. Furthermore, the AHISR leverages the institutional resources within the Vanderbilt University Institute of Imaging Science (VUIIS) to develop new and improved methods for obtaining information that addresses research questions of direct cancer relevance. More specifically, the AHISR will provide: 1. Collaborations with expert imaging science faculty (in nuclear, optical, magnetic resonance and ultrasound imaging) for the development and application of cutting-edge imaging protocols 2. Innovative and novel radiopharmaceuticals for animal and human imaging research 3. Support for imaging system operators and technical staff who will handle patient and animal preparation and monitoring as well as operate the instruments 4. Support for data analysis and for quantitative image analysis customized to specific applications including the co-registration and integration of multiple modalities, histology and proteomics. The AHISR brings together advanced equipment and diverse expertise into a comprehensive integrated resource that ensures the quality of the imaging data, and consequently, the overall quality, rigor, and reproducibility of the studies is the highest possible.
CORE 002-动物和人类影像共享资源 项目摘要/摘要 动物和人类影像共享资源(AHISR)一直得到癌症的支持 自2004年起获得中心支持补助金(CCSG)。AHISR为以下项目提供科学技术援助 在临床前和临床环境中使用生物医学成像研究癌症的实验 并继续进行开发,以满足持续的需求。与前几个周期一样,AHISR仍然是一个 VICC卓越研究专业计划(SPORT)的关键组成部分,包括 最近更新了具有成像成分的乳房和胃肠道(GI)孢子。2018年, AHISR是获得NCI资助的新的联合临床成像试验资源(U24)不可或缺的一部分,该资源专注于定量 使用研究性放射性药物进行癌症代谢的PET成像。此外,AHISR的专业知识 和功能使VICC和GE Health Care(GEHC)之间建立了新的合作伙伴关系,其中量化 癌症成像和放射性药物的发现是一个重要的精确肿瘤学的中心支柱项目 主动权。AHISR内的教职员工可以使用最先进的成像设备,包括 先进的3T和7T人体核磁共振系统,研究专用的PET/CT,超声波扫描仪和 多模式动物成像和研究放射性药物的综合设施 为人类所用。此外,AHISR利用范德比尔特大学内部的机构资源 影像科学研究所(VUIIS)开发新的和改进的信息获取方法 解决与癌症直接相关的研究问题。更具体地说,AHISR将提供: 1.与成像科学专家合作(在核、光学、磁共振和 超声成像)用于开发和应用尖端成像协议 2.用于动物和人体影像研究的创新和新型放射性药物 3.为处理病人和动物准备的成像系统操作员和技术人员提供支持 以及监控和操作仪器 4.支持数据分析和针对特定应用定制的定量图像分析,包括 多种模式、组织学和蛋白质组学的共同注册和整合。 AHISR汇集了先进的设备和多样化的专业知识,形成了一个全面的 确保成像数据质量的资源,从而确保整体质量、严谨性和 研究的重现性是最高的。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Henry Charles Manning其他文献

Henry Charles Manning的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Henry Charles Manning', 18)}}的其他基金

Quantitative Imaging of OXPHOS in Pancreatic Cancer
胰腺癌中 OXPHOS 的定量成像
  • 批准号:
    10649885
  • 财政年份:
    2023
  • 资助金额:
    $ 25.16万
  • 项目类别:
Quantitative PET Imaging of Hepatocellular Carcinoma (HCC)
肝细胞癌 (HCC) 的定量 PET 成像
  • 批准号:
    9890526
  • 财政年份:
    2020
  • 资助金额:
    $ 25.16万
  • 项目类别:
Quantitative PET Imaging of Hepatocellular Carcinoma (HCC)
肝细胞癌 (HCC) 的定量 PET 成像
  • 批准号:
    10687038
  • 财政年份:
    2020
  • 资助金额:
    $ 25.16万
  • 项目类别:
Quantitative PET Imaging of Hepatocellular Carcinoma (HCC)
肝细胞癌 (HCC) 的定量 PET 成像
  • 批准号:
    10267667
  • 财政年份:
    2020
  • 资助金额:
    $ 25.16万
  • 项目类别:
Core 2: Mouse and Human Molecular Imaging
核心 2:小鼠和人类分子成像
  • 批准号:
    10700844
  • 财政年份:
    2019
  • 资助金额:
    $ 25.16万
  • 项目类别:
Core 2: Mouse and Human Molecular Imaging
核心 2:小鼠和人类分子成像
  • 批准号:
    10443609
  • 财政年份:
    2019
  • 资助金额:
    $ 25.16万
  • 项目类别:
Core 2: Mouse and Human Molecular Imaging
核心 2:小鼠和人类分子成像
  • 批准号:
    10218107
  • 财政年份:
    2019
  • 资助金额:
    $ 25.16万
  • 项目类别:
TSPO Ligands for Cancer Imaging
用于癌症成像的 TSPO 配体
  • 批准号:
    9085233
  • 财政年份:
    2016
  • 资助金额:
    $ 25.16万
  • 项目类别:
TSPO Ligands for Cancer Imaging
用于癌症成像的 TSPO 配体
  • 批准号:
    9248709
  • 财政年份:
    2016
  • 资助金额:
    $ 25.16万
  • 项目类别:
Imaging Core
成像核心
  • 批准号:
    8764764
  • 财政年份:
    2014
  • 资助金额:
    $ 25.16万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了